Table 3.

Potential specific NLRP3 inflammasome inhibitors for the treatment of endothelial dysfunction.

Agents	Targets	Host	Functions	Disease	References
MCC950	ASC oligomerization	HRECs	•↑ Endothelial viability •↓ Endothelial apoptosis	Diabetic retinopathy	112
		BMVECs	•↓ BBB permeability •↑ Vascular integrity	Diabetes mellitus	114
		Diabetic mice	•↓ Vascular dysfunction •↑ ACh vasodilation	Diabetes mellitus	113
		CLP rat	•↑ Endothelial permeability	Sepsis	115
		HUVECs/CLP mice	•↑ Aortic vasodilation •↑ p-eNOS expression	Sepsis	116
Oridonin	Cysteine 279 of NLRP3	HUVECs	•↓ Vascular inflammation	Vascular inflammation	119
		HUVECs	•↓ Angiogenesis	Breast cancer	120
Tranilast	NLRP3 oligomerization	ApoE−/− mice	•↓ Vascular inflammation •↓ Atherosclerosis	Atherosclerosis	118